Bill > HB1390

This bill creates a task force to study alternative funding programs for prescription drugs in Mississippi, with the goal of understanding how these programs impact patient access to affordable medications. The task force will be composed of members from the Mississippi Rare Disease Advisory Council or their designees, with a physician experienced in treating rare diseases serving as chairman. The task force will investigate the history and prevalence of alternative funding programs, their business models, and potential impacts on patient assistance programs and prescription medication coverage across different insurance products. The study will examine how these programs affect health insurance for commercial plans, public employees, and individual exchange plans. By December 1, 2025, the task force must complete its study and submit copies to various medical and pharmaceutical associations, as well as provide a written report with findings and legislative recommendations to the Governor, state committees, and other key state officials. Task force members will serve without compensation but may be reimbursed for travel expenses. The task force will automatically terminate after submitting its study, with the first meeting scheduled to occur by May 15, 2025.

Health and Social Services

https://billstatus.ls.state.ms.us/2025/pdf/history/HB/HB1390.xml